DSL(SH:603233)2019-04-29 16:00Financial Performance - Net profit attributable to shareholders rose by 25.20% to CNY 184,050,335.62 year-on-year[4] - Operating revenue grew by 26.77% to CNY 2,578,495,087.21 compared to the same period last year[4] - Basic earnings per share increased by 24.32% to CNY 0.46 per share[5] - The weighted average return on net assets improved by 0.68 percentage points to 5.88%[5] - The company reported a significant increase in other income, amounting to ¥4,405,875.09, mainly from new government subsidies[13] - The total profit for Q1 2019 was CNY 246,963,515.83, compared to CNY 197,020,252.76 in Q1 2018, marking a growth of 25.29%[32] - The company's operating profit for Q1 2019 was CNY 245,421,022.96, an increase from CNY 195,853,191.43 in Q1 2018, which is a rise of 25.36%[32] - Net profit for Q1 2019 was ¥514,680,466.52, compared to ¥466,388,846.64 in Q1 2018, representing an increase of approximately 10%[30] Assets and Liabilities - Total assets increased by 5.74% to CNY 6,912,014,597.22 compared to the end of the previous year[4] - The company reported a significant decrease in other current assets, down 58.70% to ¥86,799,941.54, primarily due to reduced purchases of financial products[13] - Long-term equity investments increased by 39.46% to ¥7,204,372.06, mainly due to new external investments[13] - Total liabilities as of March 31, 2019, were CNY 3.62 billion, up from CNY 3.45 billion at the end of 2018, representing an increase of about 5%[27] - The company's equity attributable to shareholders reached CNY 3.22 billion, an increase from CNY 3.04 billion at the end of 2018, indicating a growth of approximately 5.9%[27] - Current liabilities rose to ¥3,425,311,553.07, compared to ¥3,040,831,982.91, reflecting an increase of 12.7%[29] - Total assets reached approximately $5.00 billion, while total liabilities were about $3.06 billion, resulting in total equity of approximately $1.94 billion[48] Cash Flow - Net cash flow from operating activities surged by 4,721.77% to CNY 250,182,613.16 compared to the previous year[4] - Cash flow from operating activities for Q1 2019 was CNY 2,898,827,282.82, compared to CNY 2,353,269,812.76 in Q1 2018, indicating a growth of 23.19%[37] - Operating cash inflow totaled CNY 3,526,690,329.04, an increase from CNY 2,848,635,865.40 in the previous year, representing a growth of approximately 24%[38] - Cash inflow from other operating activities was CNY 627,863,046.22, compared to CNY 495,366,052.64 in the previous year, showing an increase of approximately 27%[38] - Cash outflow for investment activities was CNY 257,424,972.34, compared to CNY 1,013,461,456.96 in the previous year, indicating a decrease of approximately 75%[39] Shareholder Information - The number of shareholders at the end of the reporting period was 8,998[10] - The top shareholder, Ke Yunfeng, holds 22.5% of the shares, totaling 89,992,821 shares[10] Business Development - The company has not disclosed any new product developments or market expansion strategies in this report[3] - The company completed 6 mergers and acquisitions in the industry during the reporting period, including the acquisition of 100% equity of Guangdong Kangyibai Pharmaceutical Co., Ltd. for ¥7.2 million[20] - The company established a wholly-owned subsidiary, Guangxi Nanning Dacanglin Pharmaceutical Co., Ltd., with a registered capital of ¥10 million to enhance its business development in Nanning[22] Inventory and Receivables - Inventory levels rose to CNY 2.04 billion, compared to CNY 1.89 billion at the end of 2018, marking an increase of approximately 8.2%[25] - Accounts receivable increased to CNY 356.1 million from CNY 282.3 million, reflecting a rise of about 26% year-over-year[25] - The company reported a significant increase in other receivables, which rose to CNY 207.2 million from CNY 187.1 million, reflecting an increase of about 10.7%[25] Financial Instruments and Standards - The company has not reported any new financial instrument standards or lease standards adjustments for the current period[48]